Publications

Contraception:

The Gynmed Team is highly engaged in further improving the laws and regulations on contraception and abortion as well as the care and medical treatment of women. To this goal we publish new insights and findings. Following please find a list of articles from medical journals written or co-authored by members of the team. The publications are in English and German.

Securing reproductive rights
Fiala C, Weeks A, Safar P. Lancet.
2004 Mar 20;363(9413):989-90

Who Pays the Piper?
funding for contraception and abortion
By Christian Fiala, MD, PhD
Conscience, vol. xxxiii—no. 1 2012
viewer.zmags.com
download pdf

Abortion:

Effect of bacterial vaginosis on the pharmacokinetics of misoprostol in early pregnancy.
Sioutas A, Sandström A, Fiala C, Watzer B, Schweer H, Gemzell-Danielsson K.
Hum Reprod. 2012 Feb;27(2):388-93
www.ncbi.nlm.nih.gov

Evaluation of Early Medical Abortion (EMA) Pilot Sites
Roger Ingham and Ellie Lee et al.
University of Southampton and Department of Health, London 
www.dh.gov.uk

Providing Medical Abortion in Low-Resource Settings
An Introductory Guidebook
Gynuity, 2004/2009
download pdf

Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol
Aronsson A, Fiala C, Stephansson O, Granath F, Watzer B, Schweer H, Gemzell-Danielsson K.
Hum Reprod. 2007 Jul;22(7):1912-8
www.ncbi.nlm.nih.gov

Frequently asked clinical questions about medical abortion, WHO, 2006
www.who.int

Review of medical abortion using mifepristone in combination with a prostaglandin analogue
Fiala C, Gemzel-Danielsson K.
Contraception 2006 Jul;74(1):66-86
www.ncbi.nlm.nih.gov

Frequently asked clinical questions about medical abortion
WHO, 2006
download pdf

Pharmacokinetics of a novel oral slow-release form of misoprostol
Fiala C, Aronsson A, Granath F, Stephansson O, Seyberth HW, Watzer B, Gemzell-Danielsson K.
Hum Reproduction 2005 Dec;20(12):3414-8
www.ncbi.nlm.nih.gov

Effects of slow release misoprostol on uterine contractility in early pregnancy
C. Fiala, A. Aronsson, O. Stephansson and K. Gemzell-Danielsson
Human Reproduction 2005 Sep;20(9):2648-52.
www.ncbi.nlm.nih.gov

The effect of non-steroidal anti-inflammatory drugs (NSAIDs) on medical abortion with mifepristone and misoprostol at 13 to 22 weeks gestation
C. Fiala, ML. Swahn, O. Stephansson, and K. Gemzell-Danielsson
Human Reproduction 2005 Nov;20(11):3072-7
www.ncbi.nlm.nih.gov

Abortion in Europe: Are the Laws and Practices patient centered?
Christian Fiala
Entre Nous magazine, UNFPA/ WHO No. 59 – 2005, page 23-5
download pdf

Acceptability of home-use of misoprostol in medical abortion
Fiala C, Winikoff B, Helstrom L, Hellborg M, Gemzell-Danielsson K.
Contraception. 2004 Nov;70(5):387-92.
www.ncbi.nlm.nih.gov

Rh-prophylaxis in early abortion
Fiala C, Fux M, Gemzell Danielsson K.
Acta Obstet Gynecol Scand. 2003 Oct;82(10):892-903. Review
www.ncbi.nlm.nih.gov

Verifying the effectiveness of medical abortion; ultrasound versus hCG testing
Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K.
Eur J Obstet Gynecol Reprod Biol. 2003 Aug 15;109(2):190-5.
www.ncbi.nlm.nih.gov

Medical abortion - where we are in Europe
Christian Fiala, Entre Nous magazine, UNFPA/ WHO No 47-48; Autumn 2000: 16-17
 

Other topics:

Misoprostol and the debate over off-label drug use
Weeks AD, Fiala C, Safar P
British Journal of Obstetrics and Gynaecology. 2005 Mar;112(3):269-72.
www.misoprostol.org
download pdf